{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T07:05:12Z","timestamp":1789974312525,"version":"4.0.1"},"reference-count":17,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2027,1,1]],"date-time":"2027-01-01T00:00:00Z","timestamp":1798761600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2027,1,1]],"date-time":"2027-01-01T00:00:00Z","timestamp":1798761600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,27]],"date-time":"2026-06-27T00:00:00Z","timestamp":1782518400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["valuehealthregionalissues.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Value in Health Regional Issues"],"published-print":{"date-parts":[[2027,1]]},"DOI":"10.1016\/j.vhri.2026.101682","type":"journal-article","created":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T11:25:20Z","timestamp":1785497120000},"page":"101682","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Cost-Effectiveness of Blinatumomab for Pediatric High-Risk Relapsed Acute Lymphoblastic Leukemia in Brazil: An Economic Evaluation Using Real-World Data"],"prefix":"10.1016","volume":"57","author":[{"given":"Gutemberg Guedes","family":"Monte","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ciliana","family":"Rechenmacher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amanda","family":"Pinhatti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vinicius","family":"Lopes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gi\u00e1como","family":"Balbinotto-Neto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariana B.","family":"Michalowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liane E.","family":"Daudt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.vhri.2026.101682_bib1","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.pcl.2014.09.006","article-title":"Treatment of pediatric acute lymphoblastic leukemia","volume":"62","author":"Cooper","year":"2015","journal-title":"Pediatr Clin N Am"},{"issue":"11","key":"10.1016\/j.vhri.2026.101682_bib2","first-page":"1627","article-title":"Acute lymphoblastic leukemia: an assessment of international incidence, survival, and disease burden","volume":"26","author":"Katz","year":"2015","journal-title":"Cancer Causes Control"},{"issue":"7","key":"10.1016\/j.vhri.2026.101682_bib3","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1182\/blood-2016-03-704973","article-title":"Integration of genetic and clinical risk factors improves prognostication in relapsed childhood B-cell precursor acute lymphoblastic leukemia","volume":"128","author":"Irving","year":"2016","journal-title":"Blood"},{"issue":"14","key":"10.1016\/j.vhri.2026.101682_bib4","doi-asserted-by":"crossref","first-page":"2807","DOI":"10.1182\/blood-2012-02-265884","article-title":"How I treat relapsed childhood acute lymphoblastic leukemia","volume":"120","author":"Locatelli","year":"2012","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.vhri.2026.101682_bib5","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1080\/13696998.2016.1192549","article-title":"Healthcare burden and reimbursement of hospitalization during chemotherapy for adults with Ph-negative relapsed or refractory B-cell precursor acute lymphoblastic leukemia in France: a retrospective chart review","volume":"19","author":"Dombret","year":"2016","journal-title":"J Med Econ"},{"issue":"16","key":"10.1016\/j.vhri.2026.101682_bib6","doi-asserted-by":"crossref","first-page":"2461","DOI":"10.1016\/j.ejca.2008.08.007","article-title":"First isolated extramedullary relapse in children with B-cell precursor acute lymphoblastic leukemia: results of the Cooprall-97 study","volume":"44","author":"Domenech","year":"2008","journal-title":"Eur J Cancer"},{"issue":"31","key":"10.1016\/j.vhri.2026.101682_bib7","doi-asserted-by":"crossref","first-page":"7942","DOI":"10.1200\/JCO.2005.01.1031","article-title":"Long-term outcome in children with relapsed ALL by risk-stratified salvage therapy: results of trial ALL-REZ BFM 87","volume":"23","author":"Einsiedel","year":"2005","journal-title":"J Clin Oncol"},{"issue":"9757","key":"10.1016\/j.vhri.2026.101682_bib8","doi-asserted-by":"crossref","first-page":"2009","DOI":"10.1016\/S0140-6736(10)62002-8","article-title":"Effect of mitoxantrone on outcome of children with first relapse of acute lymphoblastic leukemia (ALL R3): an open-label randomized trial","volume":"376","author":"Parker","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.vhri.2026.101682_bib9","series-title":"Blincyto (Blinatumomab) Summary of Product Characteristics","year":"2021"},{"issue":"9","key":"10.1016\/j.vhri.2026.101682_bib10","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1056\/NEJMoa1609783","article-title":"Blinatumomab versus chemotherapy for advanced acute lymphoblastic leukemia","volume":"376","author":"Kantarjian","year":"2017","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1016\/j.vhri.2026.101682_bib11","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1001\/jama.2021.0987","article-title":"Effect of Blinatumomab vs chemotherapy on event-free survival among children with high-risk first-relapse B-cell acute lymphoblastic leukemia: a randomized clinical trial","volume":"325","author":"Locatelli","year":"2021","journal-title":"JAMA"},{"issue":"9","key":"10.1016\/j.vhri.2026.101682_bib12","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1080\/13696998.2017.1344127","article-title":"Cost-effectiveness of Blinatumomab versus salvage chemotherapy in relapsed or refractory Philadelphia chromosome-negative B-precursor acute lymphoblastic leukemia from a US payer perspective","volume":"20","author":"Delea","year":"2017","journal-title":"J Med Econ"},{"key":"10.1016\/j.vhri.2026.101682_bib13","series-title":"Diretrizes Metodol\u00f3gicas: Diretriz de Avalia\u00e7\u00e3o Econ\u00f4mica","year":"2021"},{"key":"10.1016\/j.vhri.2026.101682_bib14","series-title":"WHO-CHOICE: choosing interventions that are cost-effective","year":"2014"},{"key":"10.1016\/j.vhri.2026.101682_bib15","series-title":"Sistema de Contas Nacionais Trimestrais","year":"2023"},{"key":"10.1016\/j.vhri.2026.101682_bib17","series-title":"Decision Modelling for Health Economic Evaluation","author":"Briggs","year":"2006"},{"key":"10.1016\/j.vhri.2026.101682_bib18","series-title":"Methods for the Economic Evaluation of Health Care Programmes","author":"Drummond","year":"2015"}],"container-title":["Value in Health Regional Issues"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S221210992600097X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S221210992600097X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T06:54:18Z","timestamp":1789973658000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S221210992600097X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2027,1]]},"references-count":17,"alternative-id":["S221210992600097X"],"URL":"https:\/\/doi.org\/10.1016\/j.vhri.2026.101682","relation":{},"ISSN":["2212-1099"],"issn-type":[{"value":"2212-1099","type":"print"}],"subject":[],"published":{"date-parts":[[2027,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cost-Effectiveness of Blinatumomab for Pediatric High-Risk Relapsed Acute Lymphoblastic Leukemia in Brazil: An Economic Evaluation Using Real-World Data","name":"articletitle","label":"Article Title"},{"value":"Value in Health Regional Issues","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vhri.2026.101682","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc. on behalf of International Society for Pharmacoeconomics and Outcomes Research, Inc.","name":"copyright","label":"Copyright"}],"article-number":"101682"}}